Mary Chen Schroeder

Dr. Mary Chen Schroeder

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
ATAlexandra Thomas
Alexandra Thomas
SKSeema A. Khan
Seema A. Khan
ECElizabeth Chrischilles
Elizabeth Chrischilles
MSMary Chen Schroeder
Mary Chen Schroeder
Breast cancer is the most common malignancy in women in the United States and the developed world.1,2 Approximately 5% to 10% of women diagnosed as having breast cancer present with stage IV disease and have an intact primary breast tumor.3 While this represents a small portion of patients with breast cancer, given the prevalence of the disease, management of the primary tumor in stage IV disease remains a common clinical scenario. As with earlier-stage disease, these tumors are heterogeneous with regard to biology and disease burden. The appropriate local management of the primary tumor in stage IV breast cancer, which currently is largely considered incurable, continues to be debated.

14 March 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ATAlexandra Thomas
Alexandra Thomas
BLBrian K. Link
Brian K. Link
SASean Altekruse
Sean Altekruse
PRPaul A. Romitti
Paul A. Romitti
MSMary Chen Schroeder
Mary Chen Schroeder
Background: Primary breast lymphoma (PBL) has gained attention with the description of breast implant–associated anaplastic large cell lymphoma (ALCL). Less is known about PBL incidence, treatment, and survival by lymphoma subtype. Methods: The Surveillance, Epidemiology, and End Results (SEER) registry database was queried for patients with PBL as first malignancy, with attention to non-Hodgkin Lymphoma PBL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma (MZL), and ALCL. Incidence was estimated by age and subtype with joinpoint analyses, along with initial local therapy. Five-year relative and overall survival estimates were compared using z and two-sided log-rank tests. Results: PBL incidence (per 1 000 000 women) increased from 0.66 (1975–1977) to 2.96 (2011–2013) with an annual percentage change (APC) of 5.3% (95% confidence interval [CI] = 3.8% to 6.9%, P < .001) from 1975 to 1999 and no statistically significant change thereafter. Incidence continues to increase for women younger than age 50 years (APC = 2.8%, 95% CI = 1.0% to 4.6%, P = .003) and for ALCL-PBL (APC = 11.8%, 95% CI = 0.2% to 24.9%, P = .047) and MZL-PBL (APC = 2.3%, 95% CI = -0.2% to 4.9%, P = .07), with the latter increasing significantly from 1995 to 2013 (APC = 7.5%, 95% CI = 3.4% to 11.8%, P = .001). Surgery and surgery with radiation declined from 2000 to 2013 as initial local therapy for PBL. Five-year relative survival for PBL improved markedly over four decades and was superior for stage I DLBCL-PBL and stage I follicular PBL than for corresponding systemic presentations. Conclusions: PBL has increased in incidence over the last four decades and continues to increase for younger women and for some subtypes. The rise in imaging and procedures to the breast might enhance diagnostic sensitivity for PBL. Further study of the etiologies of PBL is needed.

23 January 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MSMary Chen Schroeder
Mary Chen Schroeder
XGXiang Gao
Xiang Gao
ILIngrid Lizarraga
Ingrid Lizarraga
AKAmanda R. Kahl
Amanda R. Kahl
MCMary E. Charlton
Mary E. Charlton

30 July 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MVMARIE VIALA
MARIE VIALA
ACAkiko Chiba
Akiko Chiba
STSimon Thezenas
Simon Thezenas
LDLaure Delmond
Laure Delmond
Pierre-Jean LamyPierre-Jean Lamy
Pierre-Jean Lamy
William JacotWilliam Jacot
William Jacot
There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associated with not attaining a pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for operable breast cancer. We report the impact of VD on pCR and survival in an expanded cohort. Patients from Iowa and Montpellier registries who had serum VD level measured before or during NAC were included. Vitamin D deficiency was defined as < 20 ng/mL. Pathological complete response was defined as no residual invasive disease in the breast and lymph nodes. Survival was defined from the date of diagnosis to the date of relapse (PFS) or date of death (OS). The study included 327 women. Vitamin D deficiency was associated with the odds of not attaining pCR (p = 0.04). Fifty-four patients relapsed and 52 patients died. In multivariate analysis, stage III disease, triple-negative (TN) subtype and the inability to achieve pCR were independently associated with inferior survival. Vitamin D deficiency was not significantly associated with survival in the overall sample; however a trend was seen in the TN (5-years PFS 60.4% vs. 72.3%, p = 0.3), and in the hormone receptor positive /human epidermal growth factor receptor 2 negative (HER2-) subgroups (5-years PFS 89% vs 78%, p = 0.056). Vitamin D deficiency is associated with the inability to reach pCR in breast cancer patients undergoing NAC.

12 July 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ILIngrid M. Lizarraga
Ingrid M. Lizarraga
MSMary Chen Schroeder
Mary Chen Schroeder
IJIsmail Jatoi
Ismail Jatoi
SSSonia L. Sugg
Sonia L. Sugg
ATAmy Trentham-Dietz
Amy Trentham-Dietz
ECElizabeth A. Chrischilles
Elizabeth A. Chrischilles

16 May 2024 in The Journal of Rural Health
Verified
Journal Article
Open access
SESydney Evans
Sydney Evans
ASAaron T. Seaman
Aaron T. Seaman
EJErin C. Johnson
Erin C. Johnson
JEJacklyn M. Engelbart
Jacklyn M. Engelbart
XGXiang Gao
Xiang Gao
MCMary E. Charlton
Mary E. Charlton
Purpose: While limited resources can make high‐quality, comprehensive, coordinated cancer care provision challenging in rural settings, rural cancer patients often rely on local hospitals for care. To develop resources and strategies to support high‐quality local cancer care, it is critical to understand the current experiences of rural cancer care physicians, including perceived strengths and challenges of providing cancer care in rural areas. Methods: Semi‐structured interviews were conducted with 13 cancer providers associated with all 12 non‐metropolitan/rural Iowa hospitals that diagnose or treat >100 cancer patients annually. Iterative thematic analysis was conducted to develop domains.Findings: Participants identified geographic proximity and sense of community as strengths of local care. They described decision‐making processes and challenges related to referring patients to larger centers for complex procedures, including a lack of dedicated navigators to facilitate and track transfers between institutions and occasional lack of respect from academic physicians. Participants reported a desire for strengthening collaborations with larger urban/academic cancer centers, including access to educational opportunities, shared resources and strategies to collect and monitor data on quality, and clinical trials.Conclusions: Rural cancer care providers are dedicated to providing high‐quality care close to home for their patients and would welcome opportunities to increase collaboration with larger centers to improve coordination and comprehensiveness of care, collect and monitor data on quality of care, and access continuing education opportunities. Further research is needed to develop implementation approaches that will extend resources, services, and expertise to rural providers to facilitate high‐quality cancer care for all cancer patients.